Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05495204 · ClinicalTrials.gov registry record
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
A clinical trial, sponsored by Epividian.
- Completed
- Registry status
- 141
- Enrollment target
NCT05495204: Completed study, sponsored by Epividian.
NCT05495204 is a clinical trial that has completed, run by Epividian. The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05495204 has completed, sponsored by Epividian.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.
Primary Outcome
Viral load \<200 copies/mL
Interventions
- DRUG Ibalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2023-02-20 |
What the finished NCT05495204 record still lists
NCT05495204 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ibalizumab is the first listed.
NCT05495204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05495204 about?
NCT05495204 is a clinical study titled "External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA". Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.
What is the current status of trial NCT05495204?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2022-08-05. Estimated completion is 2023-02-20.
What interventions are being tested in trial NCT05495204?
The interventions under investigation include: Ibalizumab (DRUG).
Who is sponsoring clinical trial NCT05495204?
This trial is sponsored by Epividian, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI